Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
- Update frequency
- every 13 days
- Average duration
- 25 minutes
- Episodes
- 116
- Years Active
- 2021 - 2025
Cellevolve Bio's Dr. Derrell Porter on the Need for Diversity and Inclusion in Biotech
We love to hear from our listeners. Send us a message.
Cellevolve Bio's founder and CEO. Dr. Derrell Porter shares his experience with starting up a cell therapy company and why we, as an industry, ne…
RNA's Advantages Over Other Cell Therapies with Cartesian's CSO
We love to hear from our listeners. Send us a message.
Dr. Michael Singer, CSO at Cartesian Therapeutics, details why RNA has advantages over other cell therapies, the company's three RNA trials, and …
Vor Biopharma's CEO on Genome Engineering of Hematopoietic Stem Cells
We love to hear from our listeners. Send us a message.
Vor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs…
AVROBIO on Patient Advocacy's Role in Clinical Trial Development & Recruitment
We love to hear from our listeners. Send us a message.
Fernanda Copeland, Global Head, Patient Advocacy & Engagement at AVROBIO, explains how to incorporate community education, patient feedback, and …
Understanding CAR-M Technology with Carisma Therapeutics' Dr. Debora Barton
We love to hear from our listeners. Send us a message.
Carisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally…
Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti
We love to hear from our listeners. Send us a message.
XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease …
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar
We love to hear from our listeners. Send us a message.
Dr. Amy Nicole Nayar, VP of US Patient Advocacy and Government Affairs at Novartis Gene Therapies explains what patient engagement should encompa…
BridgeBio's Approach to Gene Therapy & Nearing the Clinic
We love to hear from our listeners. Send us a message.
BridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperpla…
Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A
We love to hear from our listeners. Send us a message.
Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical tria…
Gene Therapies for Spinal Cord-Related Disorders with SwanBio's CEO
We love to hear from our listeners. Send us a message.
Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio, explains how the company is pioneering a deep and varied pipeline of gene therapies for gen…
Chronic Lymphocytic Leukemia: A Patient's Perspective
We love to hear from our listeners. Send us a message.
Bob Levis was diagnosed with Chronic Lymphocytic Leukemia in 2002 and was one of the early experimental trial participants at Penn Medicine for D…
State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO
We love to hear from our listeners. Send us a message.
Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector’s advancements in RNA cell therapy and the why behin…
Therapeutic Firsts and "Eds and Meds" with Penn’s Dr. Bruce Levine
We love to hear from our listeners. Send us a message.
University of Pennsylvania’s Dr. Bruce Levine explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industr…
Hospitals And Advanced Therapies with Penn Medicine’s Kevin Mahoney
We love to hear from our listeners. Send us a message.
In this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hos…
Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset
We love to hear from our listeners. Send us a message.
During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, …
Introducing Cell & Gene: The Podcast
We love to hear from our listeners. Send us a message.
Cell & Gene, the online resource that delivers in-depth content from authoritative authors and sources to professionals in the CGT sector, is thr…